Dendritic Cell Immunotherapy for Ovarian Cancer: An Overview of Our Achievements

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F24%3A10507770" target="_blank" >RIV/00216208:11130/24:10507770 - isvavai.cz</a>

Alternative codes found

RIV/00064203:_____/24:10507770

Result on the web

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=923SQPk5h7" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=923SQPk5h7</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/onco4010004" target="_blank" >10.3390/onco4010004</a>

Result language

angličtina

Original language name

Dendritic Cell Immunotherapy for Ovarian Cancer: An Overview of Our Achievements

Original language description

Epithelial ovarian carcinoma (EOC) is the fifth leading cause of cancer-related death in women, largely reflecting the early dissemination of this malignant disease to the peritoneum. Due to its immunological features, EOC has poor response to immune checkpoint inhibitors (ICIs), including a limited tumor mutational burden (TMB), poor infiltration by immune cells, and active immunosuppression. Thus, novel strategies are needed to overcome the frequent lack of pre-existing immunity in patients with EOC. We developed and tested an autologous dendritic cell (DC)-based vaccine (DCVAC), which has recently been shown to be safe and to significantly improve progression-free survival (PFS) in two independent randomized phase II clinical trials enrolling patients with EOC (SOV01, NCT02107937; SOV02, NCT02107950). In addition, our exploratory data analyses suggest that the clinical benefits of the DCVAC were more pronounced in patients with EOC with lower-than-median TMBs and reduced CD8&lt;sup&gt;+&lt;/sup&gt; T cell infiltration. Thus, the DC-based vaccine stands out as a promising clinical tool to jumpstart anticancer immunity in patients with immunologically &quot;cold&quot; EOC. Our findings underscore the need for personalized immunotherapy and the clinical relevance of potential tumor-related biomarkers within the immunotherapy field. Additional clinical trials are needed to address these strategies as well as the potential value of the TMB and immune infiltration at baseline as biomarkers for guiding the clinical management of EOC.

Czech name

—

Czech description

—

Type

J_SC - Article in a specialist periodical, which is included in the SCOPUS database

CEP classification

—

OECD FORD branch

30102 - Immunology

Project

<a href="/en/project/NU22-03-00300" target="_blank" >NU22-03-00300: LL-37 as a novel and powerful molecular tool for boosting the performance of ex vivo-produced dendritic cells in immunotherapy of urogenital cancers</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Onco

ISSN

2673-7523

e-ISSN

2673-7523

Volume of the periodical

4

Issue of the periodical within the volume

1

Country of publishing house

CH - SWITZERLAND

Number of pages

10

Pages from-to

46-55

UT code for WoS article

—

EID of the result in the Scopus database

2-s2.0-105026323237